Fig. 2: Effect of dapagliflozin on clinical outcomes across the range of ejection fraction. | Nature Medicine

Fig. 2: Effect of dapagliflozin on clinical outcomes across the range of ejection fraction.

From: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Fig. 2

a–f, Effect of dapagliflozin on: death from CV causes (a); death from all causes (b); the total number of hospital admissions for HF (c); time to first hospital admission for HF (d); death from CV causes, MI or stroke (e); and death from CV causes or hospital admission for HF (f), according to baseline LVEF. The horizontal blue line shows the continuous HR across the range of LVEF and the shaded area around this line represents the 95% CI from Cox’s model. The overall effect of treatment in the pooled population is shown in each panel as an HR (95% CI) with the two-sided P value from Cox’s model for Wald’s test of interaction between treatment and LVEF. No adjustment for multiple comparisons was made. aRestricted cubic spline and interaction P value derived from LWYY model for total HF hospitalization.

Back to article page